CMP Testing Market to Reach $28.9 Billion by 2036 as CAGR Holds at 6.4%

1 articles · Updated · futuremarketinsights.com · Aug 10

FMI pegs the global CMP testing market at $15.6 billion in 2026 and forecasts it will grow to $28.9 billion by 2036, driven by recurring test volumes rather than one-off equipment replacement cycles.
Routine care, inpatient monitoring, preoperative workups and chronic disease follow-up keep orders flowing, while suppliers capture value only when labs can deliver full panels efficiently and at low cost per reportable result.
Routine CMP tests hold a 42.0% share in 2026, routine health assessment leads applications at 34.0%, hospitals account for 38.0% of end-user demand, and automated clinical chemistry analyzers lead technology with 44.0%.
The USA posts the fastest profiled country growth at 6.8%, ahead of Japan at 6.6% and Germany at 6.5%, reflecting differences in reimbursement, accreditation rules and laboratory network economics.
The outlook still depends on specimen quality, calibration events, reagent waste and cross-site comparability, making workflow reliability and service support as important as analyzer throughput.